Japan In Vitro Diagnostics (IVD) Market to 2024 By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Challenges, Opportunities - ResearchAndMarkets.com
The "Japan In Vitro Diagnostics (IVD) Market, By Diagnostics, Companies, Reimbursements, Porter's Model, Growth Drivers, Challenges, Opportunities" report has been added to ResearchAndMarkets.com's offering
The Japanese In Vitro Diagnostics market is expected to surpass US$4.3 Billion by the end of year 2024
In Japan, In Vitro Diagnostics comes under medical devices, which are consumable or disposable and used to collect numerous bio-samples under various medical conditions.
Japan has the highest proportion of ageing population globally; almost its quarter of population is aged 65 and over. The rise in number of older people is the biggest burden for the Japanese government because the prevalence of ageing diseases is rising at rapid pace. So the Japanese government has given priority to deal with ageing population and it is expected that the government will allocate an increased healthcare budget in 2025 for ageing. Therefore rising prevalence and increased public expenditure will boost the Japanese In Vitro Diagnostics Market in future.
This report includes an in-depth study of 11 segments of Japan In Vitro Diagnostic Market: Urine & Feces, Hematology, Clinical Chemistry, Self Monitoring Blood Glucose (SMBG), Tumor Marker, Immunology, Infectious disease, Microbiology, Pathology, Genetic Testing and Others. The report gives you comprehensive insight of each segment of In-vitro diagnostic along with separate growth factors for each of segments.
This report explains the length and breadth of reimbursement policies along with the complete framework. It also provides clear insight & structure of how it works actually, how to take approval from Japanese authorities regarding reimbursement policies. It explains classification of medical devices in Japan and which class In vitro diagnostic fits. It covers all medical manufacturer applied for reimbursement approval in Japan for past five years.
The advancement in In vitro Diagnostic technique has made it simpler to diagnose with lesser time being less invasive. The improved digitization in pathology has gain the ability to deliver the clinical outcome within the stipulated time-frame. Japan has successfully done the trial for first urine test to diagnose cancer in the world in 2018. Moreover for colon cancer, screening is conducted via a feces test. All these technology improvement will further enhance the Japan In vitro Diagnostic market.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Outlook - Japan In-vitro Diagnostics Market
5. Market Share Analysis
6. Japan In-vitro Diagnostics Market by Segment
7. Porter's Five Forces Analysis
8. Market Dynamics
9. Reimbursement Policy
10. Abbott Laboratories - Company Analysis
11. Danaher Corporation - Company Analysis
12. Biomerieux - Company Analysis
13. Roche Diagnostics - Company Analysis
For more information about this report visit https://www.researchandmarkets.com/research/g7chcs/japan_in_vitro?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005503/en/